These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26050520)

  • 1. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review.
    Pereira WL; Reiche EM; Kallaur AP; Kaimen-Maciel DR
    J Neurol Sci; 2015 Aug; 355(1-2):7-17. PubMed ID: 26050520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neuromyelitis optica and anti-aquaporin 4 antibody--an overview].
    Misu T; Fujihara K; Itoyama Y
    Brain Nerve; 2008 May; 60(5):527-37. PubMed ID: 18516975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
    Jarius S; Paul F; Franciotta D; Waters P; Zipp F; Hohlfeld R; Vincent A; Wildemann B
    Nat Clin Pract Neurol; 2008 Apr; 4(4):202-14. PubMed ID: 18334978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
    Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
    Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optic neuritis in neuromyelitis optica.
    Levin MH; Bennett JL; Verkman AS
    Prog Retin Eye Res; 2013 Sep; 36():159-71. PubMed ID: 23545439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
    Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
    J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological autoimmunity targeting aquaporin-4.
    Hinson SR; McKeon A; Lennon VA
    Neuroscience; 2010 Jul; 168(4):1009-18. PubMed ID: 19699271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
    Roemer SF; Parisi JE; Lennon VA; Benarroch EE; Lassmann H; Bruck W; Mandler RN; Weinshenker BG; Pittock SJ; Wingerchuk DM; Lucchinetti CF
    Brain; 2007 May; 130(Pt 5):1194-205. PubMed ID: 17282996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuromyelitis optica: a clinical update].
    Chiquete E; Navarro-Bonnet J; Ayala-Armas R; Gutiérrez-Gutiérrez N; Solórzano-Meléndez A; Rodríguez-Tapia D; Gómez-Rincón M; Ruiz-Sandoval JL
    Rev Neurol; 2010 Sep; 51(5):289-94. PubMed ID: 20669128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neuromyelitis optica: a separate disease entity associated with aquaporin-4-antibodies].
    Jordan B; Eger K; Kornhuber ME; Zierz S
    Fortschr Neurol Psychiatr; 2008 Jan; 76(1):21-7. PubMed ID: 18189220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G.
    Yao X; Verkman AS
    Acta Neuropathol Commun; 2017 Feb; 5(1):15. PubMed ID: 28212662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromyelitis optica.
    Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
    Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of neuromyelitis optica.
    Wingerchuk DM; Lennon VA; Lucchinetti CF; Pittock SJ; Weinshenker BG
    Lancet Neurol; 2007 Sep; 6(9):805-15. PubMed ID: 17706564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuromyelitis optica and anti-aquaporin 4 antibody--distinct from multiple sclerosis].
    Misu T; Takahashi T; Nakashima I; Fujihara K; Itoyama Y
    Rinsho Byori; 2009 Mar; 57(3):262-70. PubMed ID: 19363997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica: concept, immunology and treatment.
    Uzawa A; Mori M; Kuwabara S
    J Clin Neurosci; 2014 Jan; 21(1):12-21. PubMed ID: 23916471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO).
    Asgari N
    Dan Med J; 2013 Oct; 60(10):B4730. PubMed ID: 24083534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
    Misu T; Fujihara K; Kakita A; Konno H; Nakamura M; Watanabe S; Takahashi T; Nakashima I; Takahashi H; Itoyama Y
    Brain; 2007 May; 130(Pt 5):1224-34. PubMed ID: 17405762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
    Wu Y; Zhong L; Geng J
    Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica.
    Saikali P; Cayrol R; Vincent T
    Autoimmun Rev; 2009 Dec; 9(2):132-5. PubMed ID: 19389490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.
    Chan KH; Ramsden DB; Yu YL; Kwok KH; Chu AC; Ho PW; Kwan JS; Lee R; Lim E; Kung MH; Ho SL
    Eur J Neurol; 2009 Mar; 16(3):310-6. PubMed ID: 19138340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.